CF PharmTech, Inc. Secures NMPA Approval for Clinical Trial of Novel Nasal Spray Targeting Allergic Rhinitis

Hong Kong, March 9, 2026 – CF PharmTech, Inc. (Stock Code: 2652), a leading innovator in inhalation drug delivery, has announced a significant development for its research and development pipeline: the National Medical Products Administration (NMPA) of China has approved its clinical trial application (CTA) for a new fixed-dose combination nasal spray containing olopatadine hydrochloride and mometasone furoate monohydrate. This marks the first generic clinical trial application for this particular product in China, highlighting the company’s pioneering status in the domestic market.

Key Points of the Announcement

• Product: Olopatadine hydrochloride and mometasone furoate monohydrate nasal spray
• Application Type: Clinical trial application for domestic drug registration
• Acceptance Numbers: CYHL2500215/CYHL2500214
• Proposed Indication: Treatment of moderate-to-severe allergic rhinitis in adults and children aged 12 and above
• Innovation: The product is a fixed-dose combination of an antihistamine (olopatadine) and a corticosteroid (mometasone), aiming to address unmet clinical needs by improving convenience and patient compliance in allergic rhinitis treatment
• Market Position: CF PharmTech is the first in China to submit a generic clinical trial application for this combination, giving it a potential first-mover advantage in a large and growing market

Strategic and Commercial Significance

• Milestone Achievement: The CTA approval enables the product to move into the clinical trial phase, a critical step toward commercialization.
• High Technical Barriers: Developing fixed-dose combination nasal sprays presents substantial formulation, stability, and manufacturing challenges. The company’s success in achieving this approval demonstrates robust execution capabilities in complex drug-device integration.
• Portfolio Expansion: This new product complements CF PharmTech’s existing portfolio for allergic rhinitis (AR) and chronic rhinosinusitis (CRS), which already includes:
• Azelastine hydrochloride and fluticasone propionate nasal spray (Shu Fei Min®)
• Mometasone furoate nasal spray
• Budesonide nasal spray
• Comprehensive Solutions: The company now covers a wide range of age groups and disease stages, positioning itself as a leader in upper airway disease management for both domestic and potentially global markets.

Further Details and Company Positioning

• Integrated Capabilities: CF PharmTech’s strengths include device engineering, precision drug delivery, global regulatory filing, and commercialization. Its end-to-end capabilities, ranging from exhalation-powered nasal spray delivery to liposomal inhalation and siRNA nucleic acid platforms, support a strong proprietary pipeline targeting China, the US, and Europe.
• Therapeutic Focus: Current and pipeline products address:
• Respiratory diseases (asthma, COPD, bronchiectasis)
• Nasal diseases (allergic rhinitis, chronic rhinosinusitis)
• Strategic expansion into pulmonary fibrosis, pulmonary arterial hypertension, rare pulmonary infections, and central nervous system disorders (via nose-to-brain delivery)
• Commercial Network: The company boasts a multi-dimensional commercialization network in China and is expanding its global presence through compliant manufacturing and international outreach, reinforcing its ambition to become a global leader in innovative pharmaceuticals.

Potential Price-Sensitive and Shareholder-Relevant Information

• First-in-China Status: Being the first to submit a generic clinical trial application for this combination product may confer significant commercial benefits, including potential market exclusivity and accelerated revenue opportunities if successful.
• Pipeline Validation: The CTA approval serves as validation of the company’s R&D and execution in high-barrier, value-added pharmaceutical products, which may positively impact investor sentiment and share value.
• Portfolio Synergy: The addition of this product to the company’s AR/CRS portfolio enhances its offering and could increase market share, especially as the product targets moderate-to-severe cases with unmet needs.

Risk Factors and Investor Considerations

• The pharmaceutical sector is inherently high-risk, high-tech, and high-value-added. Successful CTA approval does not guarantee favorable clinical results, further marketing approval, or eventual commercialization.
• Shareholders and potential investors should be aware of the substantial risks and uncertainties associated with drug development.

Leadership and Governance

• Key Executives: Dr. LIANG Bill Wenqing (Chairperson, Executive Director and CEO), Dr. LI LI BOVET, Dr. LI Qi, Ms. ZHU Yuyu (Executive Directors), Mr. CHEN Penghui, Mr. CAI Lei, Dr. YI Hua (Non-executive Directors), Dr. JIN Jian, Ms. WANG Lijuan, Mr. WEI Shirong, Mr. IP Wang Hoi (Independent Non-executive Directors).

Disclaimer: This article is provided for informational purposes only and does not constitute investment advice. The pharmaceutical industry involves significant risks and uncertainties, particularly in drug research, development, and commercialization. There is no assurance that clinical trial approval will result in successful commercialization or financial performance. Investors are advised to exercise caution and consult professional advisors before making investment decisions regarding CF PharmTech, Inc.

View CF PHARMTECH Historical chart here